Circio Holding

Less than 1K followers

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Market cap

-

Turnover

-

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

All

Press releases

ShowingAll content types

Regulatory press releaseyesterday

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Regulatory press releaseyesterday

Circio Holding ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates

Regulatory press release1/15/2026, 6:00 AM

Circio Holding ASA – Commencement of the subscription period for the rights issue

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release1/13/2026, 11:23 AM

Circio Holding ASA – Approval and publication of prospectus for the rights issue

Regulatory press release1/13/2026, 6:00 AM

CRNA: Circio Holding ASA Ex. subscription rights today

Regulatory press release1/13/2026, 6:00 AM

Circio Holding ASA – Ex. subscription rights today

Regulatory press release1/12/2026, 9:19 PM

Circio Holding ASA – Minutes from the extraordinary general meeting 2026 and approval of Rights Issue

Regulatory press release1/12/2026, 2:30 PM

Circio invites to live webcast on 15 January 2026 to provide information about the upcoming rights issue

Regulatory press release1/12/2026, 2:15 PM

Circio Holding ASA – Extraordinary general meeting held, all agenda items approved

Regulatory press release1/9/2026, 6:00 AM

Circio Holding ASA – Updated key information relating to the rights issue

Press release1/7/2026, 4:00 PM

Circio and The University of Texas Medical Branch jointly announce collaboration to evaluate circVec for the treatment of infectious diseases

Regulatory press release12/23/2025, 8:11 AM

Correction: Circio Holding ASA – Updated information to the notice of extraordinary general meeting 2026

Regulatory press release12/23/2025, 8:02 AM

Circio Holding ASA – Updated information to the notice of extraordinary general meeting 2025

Regulatory press release12/19/2025, 1:24 PM

Circio Holding ASA – Notice of extraordinary general meeting on 12 January 2026

Regulatory press release12/8/2025, 9:00 AM

Circio Holding ASA – Key information related to the rights issue

Regulatory press release12/8/2025, 6:00 AM

Circio announces 88% underwritten and presubscribed NOK 50 million rights issue with strong support from existing shareholders

Regulatory press release12/3/2025, 2:23 PM

Corr*: Atlas Holdings for CIRCIO

Regulatory press release12/3/2025, 11:36 AM

CRNA: Atlas Holdings for CIRCIO

Regulatory press release11/25/2025, 2:22 PM

CRNA: Atlas Holdings for CIRCIO

Regulatory press release11/24/2025, 6:00 AM

Circio presents data that further strengthens and broadens its circVec circular RNA expression platform

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.